• If you are trying to work out whether ACADIA Pharmaceuticals at around US$21.48 is attractively priced or not, the key question is what you are really getting for that price.
• The stock is currently around 18.3% lower year to date, yet it has returned 45.0% over the last year, a mix that can change how the market is thinking about both potential and risk.
• Recent news flow around ACADIA Pharmaceuticals has largely focused on its position in the pharmaceuticals and biotech space and how investors view its pipeline and commercial prospects. This context helps explain why the stock has seen both shorter term weakness over 7 days and 30 days, and a stronger 1 year return.
• Right now the company scores 5 out of 6 on our valuation checks. This sets up a closer look at how different valuation methods line up for ACADIA Pharmaceuticals and hints at a broader way to think about valuation that will be covered at the end of this article.

Approach 1: ACADIA Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the cash it might generate in the future and then discounting those cash flows back to today to get a present value per share.

For ACADIA Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections rather than earnings. The latest twelve month Free Cash Flow is about $53.8 million. Analysts provide specific Free Cash Flow estimates out to 2030, including $547.3 million for 2030, and Simply Wall St extrapolates further out to 2035 using gradually moderating growth assumptions. All of these projected cash flows are discounted back into today's dollars in US$.

Pulling those cash flows together, the model arrives at an estimated intrinsic value of about $97.19 per share, compared with the recent share price around $21.48. That gap implies an intrinsic discount of about 77.9%, which indicates the stock is trading well below this particular DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests ACADIA Pharmaceuticals is undervalued by 77.9%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: ACADIA Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a useful way to think about value because it directly links what you are paying for each share to the earnings that company is currently generating. It gives you a simple snapshot of how many dollars the market is willing to pay today for one dollar of earnings.

What counts as a “normal” P/E depends on what investors expect from the business and how risky they think those earnings are. Higher growth and lower perceived risk usually justify a higher P/E, while lower growth or higher risk often go with a lower P/E.

ACADIA Pharmaceuticals is trading on a P/E of about 9.41x. That is below the Biotechs industry average P/E of about 17.76x and also below the peer group average of around 31.02x. Simply Wall St’s Fair Ratio for ACADIA Pharmaceuticals is 16.62x. This Fair Ratio is a proprietary estimate of what the P/E might be given factors such as the company’s earnings growth profile, its industry, profit margins, market cap and specific risks. Because it adjusts for these company level characteristics, it can be more informative than a simple comparison with peers or the overall industry.

Comparing the current P/E of 9.41x with the Fair Ratio of 16.62x suggests the stock is trading below this multiple based estimate of fair value.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your ACADIA Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as a simple way for you to link your view of ACADIA Pharmaceuticals to numbers by turning your story about its products, risks and opportunities into a set of revenue, earnings and margin forecasts. The Simply Wall St Community page then converts these into a Fair Value that you can compare with the current price to decide whether the stock looks appealing or not. You can have this update automatically as new news or earnings arrive and see it side by side with other investors’ Narratives, such as one that assumes a cautious fair value of about US$19.64 and another that assumes a higher fair value of about US$43.97, while the consensus sits around US$31.80.

For ACADIA Pharmaceuticals, however, we will make it really easy for you with previews of two leading ACADIA Pharmaceuticals Narratives:

First is a version that leans into the opportunity around specialized care and views the stock as undervalued relative to that story.

Then there is a more cautious view that focuses on execution risk, pricing pressure and reliance on a narrow product set.

Fair value in this narrative: US$28.75 per share.

At the recent price of US$21.48, this implies the stock is about 25.3% below that narrative fair value.

Revenue growth assumption in this narrative: 10.02% a year.

• Frames ACADIA as a focused specialist in neurological and psychiatric conditions where treatment options are limited and unmet need is high.
• Highlights concentration risk but notes that successful execution in a few targeted indications can translate into meaningful clinical and financial impact.
• Emphasizes disciplined monitoring of clinical milestones, prescribing trends and management decisions as key for anyone following the stock closely.

Fair value in this narrative: US$19.64 per share.

At the recent price of US$21.48, this implies the stock is about 9.4% above that narrative fair value.

Revenue growth assumption in this narrative: 9.41% a year.

• Focuses on reliance on NUPLAZID and DAYBUE, with concern that patent cliffs, generics and pricing limits could affect revenue and margins over time.
• Builds in tighter assumptions around profit margins and share count, and uses these to anchor a lower fair value than the recent price.
• Flags regulatory decisions, reimbursement trends and pipeline execution as the main swing factors that could either support or challenge this cautious stance.

If you want to go beyond these snapshots and see how other investors are connecting their stories about ACADIA Pharmaceuticals to detailed forecasts and fair values, it is worth reviewing the wider range of Community Narratives and updating your own view as new information comes through.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for ACADIA Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for ACADIA Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.